Enhabit, Inc. (NYSE:EHAB – Get Free Report) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 1,220,000 shares, a decline of 5.4% from the December 15th total of 1,290,000 shares. Based on an average daily volume of 375,300 shares, the days-to-cover ratio is currently 3.3 days. Approximately 2.8% of the company’s stock are sold short.
Insider Transactions at Enhabit
In related news, Director Stuart M. Mcguigan purchased 15,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was bought at an average cost of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the acquisition, the director now owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. This represents a 47.15 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bolton bought 4,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the transaction, the director now owns 98,144 shares in the company, valued at $852,871.36. This trade represents a 4.25 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC boosted its stake in shares of Enhabit by 138.4% in the third quarter. FMR LLC now owns 3,388 shares of the company’s stock valued at $27,000 after purchasing an additional 1,967 shares during the period. Quarry LP lifted its stake in shares of Enhabit by 242.2% in the 2nd quarter. Quarry LP now owns 3,703 shares of the company’s stock worth $33,000 after acquiring an additional 2,621 shares during the period. Gladius Capital Management LP raised its stake in shares of Enhabit by 78.2% in the 3rd quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock worth $49,000 after buying an additional 2,747 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Enhabit by 19.6% in the 3rd quarter. Franklin Resources Inc. now owns 32,382 shares of the company’s stock worth $256,000 after purchasing an additional 5,317 shares during the last quarter. Finally, Public Sector Pension Investment Board lifted its position in shares of Enhabit by 6.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 110,385 shares of the company’s stock valued at $985,000 after acquiring an additional 6,351 shares during the last quarter.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on Enhabit
Enhabit Price Performance
Shares of NYSE EHAB opened at $7.99 on Friday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.46 and a quick ratio of 1.46. Enhabit has a 1 year low of $6.85 and a 1 year high of $11.74. The company’s fifty day moving average price is $7.83 and its 200 day moving average price is $8.11.
Enhabit (NYSE:EHAB – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The business had revenue of $253.60 million during the quarter, compared to analyst estimates of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter last year, the firm posted $0.03 EPS. Equities analysts forecast that Enhabit will post 0.22 earnings per share for the current fiscal year.
Enhabit Company Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
See Also
- Five stocks we like better than Enhabit
- How to Use the MarketBeat Excel Dividend Calculator
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- What is the Hang Seng index?
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- How to Use Stock Screeners to Find Stocks
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.